MIF-1 (Pro-Leu-Gly-NH₂)

MIF-1 (Pro-Leu-Gly-NH₂; melanostatin, MSH-release-inhibiting factor 1) is an endogenous tripeptide (Pro-Leu-Gly-NH₂, abbreviated PLG) formed by cleavage of the C-terminal fragment of oxytocin.

What research looks at

The best-documented pharmacology of MIF-1 is positive allosteric modulation of dopamine D2 and D4 receptors: the peptide binds a site distinct from the orthosteric pocket and enhances the receptor's response to dopamine. MIF-1 resists degradation in plasma and crosses the blood–brain barrier directly. It was first isolated as a factor that inhibits release of melanocyte-stimulating hormone (MSH) — hence the name “melanostatin”.

In preclinical work and small early clinical studies, MIF-1 and its peptidomimetics were examined in Parkinson's disease (levodopa potentiation) and depression. The evidence base is limited, largely old and mixed — mostly small 1970s–1990s studies and animal models, with no modern large randomised trials. MIF-1 is not an approved medicine and its clinical efficacy in humans is not established. A referenced review is in the monograph.

Status and format

This listing is currently not for sale (coming soon). The batch specification and certificate of analysis (HPLC purity, mass confirmation by mass spectrometry) will be published before sales begin.